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Abstract
Background: Despite intensive effort, currently no effective anti-Ras therapies have successfully
reached clinical application. Previous studies suggest that the histone deacetylatse (HDAC)
inhibitor romidepsin, which is currently in clinical trials for the treatment of multiple malignancies,
can block Ras-dependent signaling and growth transformation. These studies suggest that
mutational activation of Ras may be a useful biomarker for sensitivity to romidepsin and that the
anti-tumor activity of this HDAC inhibitor may involve inhibition of Ras effector-mediated signaling.
Results:  To rigorously assess romidepsin as an antagonist of Ras, we utilized two well-
characterized cell models for Ras transformation. We found that romidepsin blocked the
anchorage-dependent and -independent growth of NIH 3T3 fibroblasts and RIE-1 epithelial cells
transformed by all three Ras isoforms. However, romidepsin treatment also blocked growth
transformation caused by other oncoproteins (B-Raf and ErbB2/Neu), suggesting that romidepsin
is not selective for Ras. We also observed striking differences in romidepsin-mediated growth
inhibition between transformed NIH 3T3 fibroblasts compared to RIE-1 epithelial cells, suggesting
that the mechanism by which romidepsin blocks transformation is dependent on cellular context.
Finally, we found that romidepsin did not inhibit Ras activation of the ERK and AKT effector
pathways in NIH 3T3 and RIE-1 cells, suggesting that romidepsin does not directly antagonize Ras.
Conclusion:  Taken together, our results suggest that romidepsin is not selective for Ras-
transformed cells and that the anti-tumor activity of romidepsin is not due to direct inhibition of
Ras function.
Background
Romidepsin (also called FK228, depsipeptide) is a bicyclic
depsipeptide that was isolated from Chromobacterium viol-
aceum and potently inhibits tumor growth [1,2]. The his-
tone deacetylase (HDAC) family of enzymes was
identified as the biologic target of romidepsin [3].
Romidepsin is a potent inhibitor of class I HDACs and, to
a lesser extent, inhibits class II HDACs [4]. HDACs are
involved in chromatin remodeling and transcriptional
silencing, including the epigenetic silencing of several
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tumor suppressors [5]. Altered HDAC activity has been
found in several cancers [5,6] and HDAC inhibitors have
been shown to reverse cancer-associated epigenetic
changes and cause growth arrest, differentiation, and
apoptosis in cancer cell lines [6]. Therefore, romidepsin
and other HDAC inhibitors have emerged as promising
therapeutics for the treatment of cancer [4,6-8]. Presently,
romidepsin and other HDAC inhibitors are under Phase I
and II clinical evaluation [9].
The mechanistic basis for the anti-tumor activity of HDAC
inhibitors remains poorly understood and is a topic of
intense investigation [4,6-8]. While altered gene transcrip-
tion is believed to be an important component of HDAC
inhibitor activity, there is also evidence for altered func-
tion of signal transduction regulators. For example, there
is evidence that mutational activation of H-Ras increases
sensitivity to romidepsin-induced apoptosis and growth
inhibition and that this HDAC inhibitor may block the
function and signaling of the H-Ras oncoprotein [10,11].
The three RAS oncogenes (HRAS, KRAS and NRAS) are
mutationally activated in ~30% of all cancers and are
implicated in promoting multiple aspects of the malig-
nant cancer phenotype [12-15]. Therefore, considerable
effort has been made to develop anti-Ras inhibitors for
cancer treatment. However, selective and clinically active
Ras inhibitors have not yet been identified [13]. Romidep-
sin was described originally as an agent that reverted the
transformed morphology of H-Ras-transformed NIH 3T3
mouse fibroblasts [1,16]. Romidepsin was further shown
to inhibit the proliferation of H-Ras-transformed NIH 3T3
and C3H10T1/2 mouse fibroblasts [1,17]. However,
HRAS mutations are rarely seen in human cancers (4%),
and whether romidepsin also inhibits transformation
caused by the Ras isoforms most commonly mutated in
human cancers (KRAS and NRAS; 21 and 8%, respectively
[18]) has not yet been addressed. This issue is important
in light of growing evidence for isoform differences in Ras
function [19]. Furthermore, while there is limited evi-
dence that Ras-transformed cells display enhanced sensi-
tivity to romidepsin-induced apoptosis [10,11], whether
RAS mutation status will be a useful molecular determi-
nant for HDAC inhibitor sensitivity is not yet known.
Ras functions as a GTP/GDP regulated switch that relays
cellular signals involved in cell proliferation, differentia-
tion, and survival [20]. In its GTP-bound state, Ras binds
and activates a variety of effectors, including the Raf ser-
ine/threonine kinases and the phosphatidylinositol 3-
kinases (PI3Ks), resulting in phosphorylation and activa-
tion of ERK and AKT, respectively. Several studies
observed that romidepsin treatment inhibited Ras activa-
tion of ERK and AKT [17,21-23], although the relevance of
these activities to romidepsin anti-tumor activity has not
been established. Furthermore, other studies have made
conflicting observations regarding the effects of romidep-
sin on Ras signaling [10,24].
To directly address the ability of romidepsin to antagonize
Ras-mediated growth transformation and signaling, we
utilized two model cell systems where mutationally acti-
vated Ras alone is sufficient and necessary for growth
transformation. Ras-transformed NIH 3T3 and RIE-1 cells
have been used extensively to study Ras-mediated trans-
formation and signaling [25-27]. Our data suggest that
romidepsin can inhibit growth transformation caused by
mutant Ras, but is not selective for Ras-transformed cells.
In contrast to previous observations that found that onco-
genic Ras increased romidepsin-induced caspase-3 cleav-
age [10,11,17,28], we did not find that Ras rendered cells
more sensitive to romidepsin-induced caspase-3 or PARP
cleavage at concentrations that blocked growth transfor-
mation. Instead, our results suggest that romidepsin
causes cell cycle arrest in these cell lines. Finally, our
results reveal that romidepsin treatment did not inhibit
ERK and AKT activity, suggesting that romidepsin does
not directly antagonize Ras function.
Methods
Cell culture and generation of stable cell lines
NIH 3T3 mouse fibroblasts were maintained in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% calf serum (Colorado Serum Company, Denver,
CO). RIE-1 rat intestinal epithelial cells were maintained
in DMEM supplemented with 10% fetal calf serum
(Sigma-Aldrich, St. Louis, MO). To generate mass popula-
tions of NIH 3T3 and RIE-1 cell lines stably expressing
ectopic oncogenic proteins, infectious retrovirus of the
pBabe-puro vectors encoding mutationally activated
human H-Ras (G12V), K-Ras4B (G12V), N-Ras (G12D),
B-Raf (V600E), and rat ErbB2/Neu (NeuT; V664E) was
generated and used to stably infect NIH 3T3 and RIE-1
cells. Stable cell lines were maintained in growth medium
supplemented with 1 μg/mL puromycin (Sigma-Aldrich).
Proliferation assays
Stably transformed cells were trypsinized and 1000 cells/
well (NIH 3T3) or 500 cells/well (RIE-1) were seeded in
replicates of 8 in 96-well plates. The next day, medium
was replaced with growth medium supplemented with
DMSO, or 1, 3, or 5 nM romidepsin. Viable cells were
quantified 72 h post-treatment with an MTT (3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide; Sigma) assay as described previously [29].
Growth transformation assays
Mass populations of NIH 3T3 and RIE-1 cells stably
infected with the empty pBabe-puro vector or encoding
oncogenic proteins were analyzed in soft agar assays as we
have described previously [30,31]. In triplicate, 2 × 104Journal of Molecular Signaling 2009, 4:5 http://www.jmolecularsignaling.com/content/4/1/5
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NIH 3T3 or 104 RIE-1 cells were suspended in growth
medium containing 0.4% agar and 0 (dimethylsufoxide;
DMSO; vehicle only), 1 or 3 nM romidepsin. Media con-
taining 0, 1, or 3 nM romidepsin was replenished weekly.
Cultures were maintained at 37°C for two to three weeks,
at which point viable colonies were stained with 500 μL of
0.2 mg/mL MTT viability stain (dissolved in PBS) and
incubated at 37°C for a minimum of 1 h [29]. The
number of viable colonies per plate was quantified using
ImageJ software at a threshold of 80.
Morphological reversion assays
NIH 3T3 and RIE-1 stable cell lines were seeded at a den-
sity of 3 × 104 and 4 × 104 cells per well, respectively, in 6-
well plates. The next day, cells were treated in duplicate
with 0.1% DMSO (vehicle control), 5 nM romidepsin, or
10 μM U0126 (Promega, Madison, WI). Following 48 h of
treatment, morphologic changes were monitored by vis-
ual inspection using phase-contrast microscopy and rep-
resentative fields were photographed using the 10×
objective of an inverted phase-contrast microscope
(Nikon).
Immunoblotting and antibodies
Cells growing in log phase were treated with 0.1% DMSO,
5 nM romidepsin, 10 μM U0126, or 10 μM LY294002
(Promega) for 24 h. Alternatively, cells were treated with
either 5 nM romidepsin for 72 h, or with 1 μM STS for 24
h as a positive control for induction of apoptosis. Cells
were rinsed twice in ice-cold 1× PBS and then lysed in
buffer containing 1% NP40, 1% deoxycholic acid, 0.1%
SDS, 150 mM NaCl, and 50 mM Tris-HCl (pH 7.4), sup-
plemented with EDTA-free protease inhibitor cocktail
(Roche Applied Science) and phosphatase inhibitor cock-
tail I and II (Sigma-Aldrich). Lysates were normalized for
protein concentration [determined with the Bio-Rad pro-
tein assay (Hercules, CA)], mixed with an equal volume of
2× protein sample buffer, resolved by SDS-PAGE, and
transferred onto Immobilon P membranes (Millipore,
Bedford, MA). The following primary antibodies were
used for western blot analysis: anti-caspase-3, anti-PARP,
anti-p42/44 MAPK (ERK1 and ERK2), anti-phospho-
T202/Y204-p42/44 MAPK (ERK1 and ERK2), anti-AKT,
anti-phospho-S473-AKT, anti-phospho-S608-Rb (Cell
Signaling Technology, Danvers, MA); anti-B-Raf (Santa
Cruz Biotechnology, Santa Cruz, CA); anti-pan-Ras, anti-
p21CIP1/WAF1 (CalBiochem); anti-cyclin D1 (NeoMarkers,
Fremont, CA); anti-β-actin, and anti-vinculin (Sigma-
Aldrich).
Results
Romidepsin inhibits proliferation of transformed NIH 3T3 
and RIE-1 cells, but does not exhibit enhanced sensitivity 
for Ras-transformed cells
To rigorously evaluate the possible mechanism of
romidepsin anti-tumor activity, we stably transformed
NIH 3T3 mouse fibroblasts and RIE-1 epithelial cells with
the oncogenic forms of H-, K-, and N-Ras, as well as with
oncogenic B-Raf and ErbB2/Neu. To determine if
romidepsin can selectively inhibit the growth of Ras-trans-
formed cells, the anchorage-dependent proliferation of
these cells was quantified following 72 h treatment with
romidepsin. Treatment with 1 nM romidepsin did not
drastically inhibit the anchorage-dependent proliferation
of H-, K-, and N-Ras-transformed cells, but significant
inhibition was seen at 3 to 5 nM. In contrast, treatment
with up to 5 nM caused no significant impact on the
growth of nontransformed NIH 3T3 cells (Figure 1A).
These data extend previous studies which showed that H-
Ras-transformed fibroblasts were more sensitive to
romidepsin than nontransformed cells [17,24]. Similarly,
3 to 5 nM romidepsin also inhibited the growth of ErbB2/
Neu-transformed cells. This result is consistent with the
fact that ErbB2/Neu transformation of NIH 3T3 cells is
dependent on Ras activation [32]. B-Raf(600E)-trans-
formed NIH 3T3 cells also exhibited sensitivity to
romidepsin growth inhibition at 3 or 5 nM. Since Raf
transformation is Ras-independent, this result suggests
that romidepsin inhibition of Ras-induced proliferation
does not involve direct inhibition of Ras.
To extend our analyses to an epithelial cell type, Ras-trans-
formed RIE-1 cells were also generated and tested for
anchorage-dependent proliferative capacity in the pres-
ence of romidepsin. Like transformed NIH 3T3 cells, all
oncogene-transformed RIE-1 cells showed significant
inhibition at 3 nM. Interestingly, unlike the NIH 3T3 cells,
transformed RIE-1 cells did not display an enhanced sen-
sitivity to romidepsin (Figure 1B). Instead, we observed
that the proliferation of nontransformed and transformed
RIE-1 cells showed similar sensitivity to romidepsin treat-
ment. Therefore, our data suggest cell context differences
in romidepsin activity, where oncogenic Ras or Raf selec-
tively sensitize NIH 3T3 but not RIE-1 cells to romidepsin.
Romidepsin disrupts cell cycle regulators but does not 
promote caspase-3 cleavage in NIH 3T3 and RIE-1 cells
Similar to our results above, previous studies found that
romidepsin inhibited the growth of nontransformed and
Ras-transformed cells [17]. However, these studies found
that romidepsin inhibition of nontransformed C3H10T1/
2 mouse fibroblasts was due to cell cycle arrest, whereas
inhibition of Ras-transformed C3H10T1/2 cells was due
to induction of apoptosis [17]. These studies suggested
that Ras activation rendered cells sensitive to romidepsin-
induced apoptotic activity. In order to determine whether
the growth inhibition we observed by romidepsin was
due to increased apoptosis or cell cycle arrest, we used
western blot analysis to examine the expression levels of
the cyclin-dependent kinase (CDK) inhibitor p21CIP1 in
response to romidepsin treatment in transformed and
nontransformed NIH 3T3 and RIE-1 cells. As we haveJournal of Molecular Signaling 2009, 4:5 http://www.jmolecularsignaling.com/content/4/1/5
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Romidepsin inhibits the anchorage-dependent growth of Ras-transformed NIH 3T3 and RIE-1 cells Figure 1
Romidepsin inhibits the anchorage-dependent growth of Ras-transformed NIH 3T3 and RIE-1 cells. NIH 3T3 
cells (A) and RIE-1 cells (B) stably-infected with the empty pBabe-puro vector or encoding constitutively active human H-
Ras(G12V), K-Ras(G12V), N-Ras(G12D), or B-Raf(V600E), or rat ErbB2/Neu(V664E) were seeded on day 0. On day 1, cells 
were treated with complete growth medium supplemented with DMSO (Vehicle), or 1, 3, or 5 nM romidepsin. After 72 h of 
romidepin treatment (day 3), cell viability was measured using the MTT assay. Data shown are the average ± SD of eight repli-
cate wells and are representative of three independent experiments.
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shown previously, p21 expression was increased in Ras-
transformed NIH 3T3 and RIE-1 cells (Figure 2) [33].
Romidepsin slightly increased p21 expression in non-
transformed as well as H-Ras-transformed NIH 3T3 cells
(Figure 2A). Romidepsin did not upregulate p21 expres-
sion in other transformed cells. In contrast, romidepsin
treatment strongly induced p21 expression in vector con-
trol and all Ras-transformed RIE-1 cells (Figure 2B). We
also determined if romidepsin modulates expression of
the cell cycle regulator cyclin D1. As we showed previ-
ously, cyclin D1 levels were increased in the Ras-trans-
formed NIH 3T3 and RIE-1 cell lines (Figure(s) 2A and
2B) [33]. Treatment with romidepsin partially decreased
cyclin D1 expression in transformed NIH 3T3 cells, but
not in the nontransformed vector controls (Figure 2A). In
contrast, romidepsin did not strongly affect cyclin D1
expression in the RIE-1 cells (Figure 2B). These results sug-
gest that romidepsin may inhibit proliferation, in part, by
upregulating p21 or downregulating cyclin D1 and inhib-
iting cell cycle progression.
Cyclin D1 and p21 function upstream of the retinoblast-
oma tumor suppressor protein (Rb). Thus, we asked
whether romidepsin affected Rb phosphorylation levels,
indicative of Rb inactivation. Romidepsin significantly
reduced Rb phosphorylation in Ras-transformed NIH 3T3
cells, but not in nontransformed cells (Figure 2C). This
reduction in Rb phosphorylation correlates with the sen-
sitivity to romidepsin observed in the cell viability assays
(Figure 1A): romidepsin blocked the proliferation of Ras-
transformed cells more strongly than nontransformed
NIH 3T3 cells. However, we failed to observe a significant
decrease in Rb phosphorylation in RIE-1 cells treated with
romidepsin (data not shown). Taken together, these data
indicate that romidepsin blocks cell cycle progression of
transformed NIH 3T3 and RIE-1 cells.
Previous studies have shown that romidepsin preferen-
tially promoted apoptosis and caspase-3 cleavage in
mutant Ras-transformed cells [10,11,17,24]. We also
asked whether romidepsin promotes cleavage of caspase-
3 in our stable cell lines, using the same conditions and
romidepsin concentrations that we used in the cell viabil-
ity assays. As a positive control to induce apoptosis, we
treated cells with staurosporine (STS). As expected, STS
treatment caused cleavage of caspase-3 and its target
PARP. However, we did not observe enhanced cleavage of
caspase-3 or PARP following 72 h of romidepsin treat-
ment of Ras-transformed NIH 3T3 or RIE-1 cells (Figure
3). Interestingly, we observed elevated caspase-3 and
PARP cleavage in untreated N-Ras-transformed RIE-1
cells, suggesting that these cells undergo apoptosis at a
higher rate than other Ras-transformed or untransformed
cells (Figure 3B). These observations are consistent with
the lack of obvious morphologic alterations indicative of
apoptosis in romidepsin-treated cells, but seen in STS-
treated cells (data not shown). We also failed to observe
annexin V staining in romidepsin-treated cells (data not
shown). Thus, in contrast to previous observations
[10,11,17,24], we did not find that Ras-transformed cells
showed enhanced sensitivity to romidepsin-induced
apoptosis under the conditions in which romidepsin
inhibited cell proliferation.
Romidepsin inhibits the anchorage-independent growth of 
transformed NIH 3T3 and RIE-1 cells
To extend previous biological studies, we analyzed the
impact of romidepsin on the anchorage-independent
growth of NIH 3T3 and RIE-1 cells. The ability of cells to
survive and grow in soft agar, in an anchorage-independ-
ent manner, strongly correlates with tumorigenic growth
potential  in vivo. As expected, nontransformed (vector
control) NIH 3T3 and RIE-1 cells displayed limited
growth in the soft agar assay, whereas all oncogene-trans-
formed cells exhibited efficient colony formation activity
(Figure 4). For all transformed NIH 3T3 cell lines, 1 nM
romidepsin effectively eliminated growth, reducing col-
ony formation by over 95%. Therefore, romidepsin more
potently inhibited the anchorage-independent growth of
Romidepsin affects expression of cell cycle regulators Figure 2
Romidepsin affects expression of cell cycle regula-
tors. NIH 3T3 (A, C) or RIE-1 (B, D) cells stably expressing 
the indicated proteins were treated with DMSO (Vehicle) or 
the indicated concentration of romidepsin for 24 h. Cell 
lysates were analyzed by western blotting with antibodies to 
cyclin D1, p21, phospho-S608-Rb, and β-actin (loading con-
trol). Data shown are representative of at least two inde-
pendent experiments.
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both Ras- and B-Raf-transformed NIH 3T3 cells than the
anchorage-dependent growth of these cells.
For oncogene-transformed RIE-1 cells, 1 nM romidepsin
only moderately reduced anchorage-independent growth
(1457% reduction in colonies; Figure 4B), in contrast to
the strong reduction in soft agar growth of the trans-
formed NIH 3T3 cells at this concentration. Treatment
with 3 nM romidepsin dramatically reduced the anchor-
age-independent growth of all transformed RIE-1 cells
(7495% reduction in colonies; Figure 4B), consistent with
the observations in NIH 3T3 cells, where romidepsin
more potently inhibits anchorage-independent growth
than anchorage-dependent growth.
Romidepsin causes partial morphological reversion in RIE-
1 cells
A hallmark of Ras transformation of NIH 3T3 and RIE-1
cells is the appearance of dramatic changes in cell mor-
phology, reflecting reduced cell attachment and spread-
ing. This morphology can be reverted to a more normal
morphology with pharmacologic inhibitors of Ras signal-
ing, for example, inhibitors of MEK activation of ERK
[33,34]. To determine whether romidepsin can cause
morphological reversion of cells transformed by K- and N-
Ras, we treated our NIH 3T3 stable cell lines with 1, 5 or
10 nM romidepsin for 48 h (Figure 5 and data not
shown). While romidepsin caused slight cell flattening
and changes in cell shape (as determined by phase con-
trast microscopy), it did not cause substantial morpholog-
ical reversion in NIH 3T3 cells. In contrast, treatment with
the MEK inhibitor U0126, which blocks ERK activation,
caused more substantial morphological reversion in the
Ras- and Raf-transformed NIH-3T3 cells (Figure 5A), sug-
gesting that romidepsin functions by a mechanism dis-
tinct from inhibition of Ras- or Raf-mediated MEK-ERK
activation.
We also asked whether romidepsin could reverse the
transformed morphology of RIE-1 cells. In contrast to the
NIH 3T3 cells, 5 nM romidepsin did cause significant
Romidepsin does not induce cleavage of caspase-3 or PARP Figure 3
Romidepsin does not induce cleavage of caspase-3 or 
PARP. NIH 3T3 cells (A) and RIE-1 cells (B) stably infected 
with pBabe.puro vector or encoding H-Ras(G12V), K-
Ras(G12V), or N-Ras(G12D) were treated with 5 nM 
romidepsin for 72 h or 1 μM staurosporine (STS) for 24 h. 
Cell lysates were analyzed by western blotting with antibod-
ies to PARP, caspase-3, and β-actin (loading control). Data 
shown are representative of at least three independent 
experiments.
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Romidepsin inhibits anchorage-independent growth of trans- formed NIH 3T3 and RIE-1 cells Figure 4
Romidepsin inhibits anchorage-independent growth 
of transformed NIH 3T3 and RIE-1 cells. NIH 3T3 cells 
(A) and RIE-1 cells (B) stably expressing the indicated pro-
teins were evaluated for colony formation in soft agar in 
complete growth medium supplemented with the indicated 
concentrations of romidepsin. Following 23 d (NIH 3T3) or 
15 d (RIE-1), viable colonies were stained in MTT and plates 
were scanned. The number of colonies was quantified from 
the scanned images using ImageJ software. Data shown are 
the average ± SD of triplicate plates and are representative 
of two independent experiments.
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morphological changes in the RIE-1 cells (Figure 5B).
Romidepsin treatment caused significant cell spreading in
the nontransformed cells. Romidepsin altered the mor-
phology of the cells transformed by the three different Ras
isoforms to varying degrees: while romidepsin had mini-
mal effects on the morphology of K-Ras-transformed cells,
it caused morphological reversion (characterized by a
decrease in cell refractility, and in increase in cell spread-
ing, amount of cytoplasm, and cell size) in ~20% of H-
Ras-transformed cells and caused substantial morpholog-
ical reversion (greater than 50%) in the N-Ras- and ErbB2/
Neu-transformed RIE-1 cells (Figure 5B). Similar results
were obtained following 72 h treatment with romidepsin
(data not shown). In contrast, treatment with U0126
caused near-complete morphological reversion of all
transformed RIE-1 cells (Figure 5B). These data reveal iso-
form-specific differences in Ras-mediated transformation
and show that romidepsin can partially revert the mor-
phology of Ras-transformed RIE-1, but not NIH 3T3, cells.
Romidepsin does not disrupt endogenous or ectopic 
expression of Ras or B-Raf
A previous study found that romidepsin treatment of
human lung carcinoma cell lines reduced the steady-state
levels of various signaling proteins, including Raf-1,
which may account for inhibition of ERK signaling [21].
To determine whether romidepsin inhibition of Ras trans-
formation involved loss of protein stability, we treated the
NIH 3T3 and RIE-1 stable cell lines with 5 nM romidepsin
for 24 h and probed lysates with antibodies to Ras and B-
Romidepsin more significantly alters the morphology of RIE-1 cells than that of NIH 3T3 cells Figure 5
Romidepsin more significantly alters the morphology of RIE-1 cells than that of NIH 3T3 cells. NIH 3T3 (A) or 
RIE-1 (B) cells stably expressing the indicated proteins were incubated in complete growth medium supplemented with DMSO 
(Vehicle), 5 nM romidepsin, or 10 μM U0126 for 48 h. Representative fields of cells were photographed under 10× magnifica-
tion. Data shown are representative of at least two independent experiments.
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Raf. As expected, Ras levels were increased in the cells sta-
bly infected with retrovirus vectors encoding activated H-
, K-, or N-Ras, with K-Ras levels being the highest (Figures
6A and 6B). Romidepsin treatment did not change the
steady-state levels of endogenous or ectopic Ras protein.
Similarly, B-Raf levels were increased in mutant B-Raf-
transformed cells and were not changed with romidepsin
treatment. These results confirmed continued expression
of the endogenous and ectopically expressed oncopro-
teins and show that romidepsin treatment did not pro-
mote their degradation and loss.
Romidepsin does not inhibit Ras signaling to ERK or AKT
Since previous studies suggested that romidepsin may
impair Ras-mediated activation of these two pathways
[17,21-23], we determined whether romidepsin treatment
inhibited Ras-induced activation of ERK or AKT in our
cells. We treated the transformed NIH 3T3 and RIE-1 cells
with 5 nM romidepsin (to be consistent with previous
studies [17]) for 24 h and probed lysates with antibodies
to phospho-ERK and phospho-AKT. In the absence of
romidepsin, phospho-ERK levels were increased in all
transformed NIH 3T3 and RIE-1 cell lines compared to the
nontransformed cells (Figure 6B). The MEK inhibitor
U0126, a control for phospho-ERK inhibition, efficiently
reduced levels of phospho-ERK in both NIH 3T3 and RIE-
1 cells (Figures 6A and 6B). In contrast, romidepsin did
not significantly change phospho-ERK levels. Thus, our
results contrast with some previous studies and argue that
inhibition of ERK activation does not contribute to the
anti-proliferative activity of romidepsin.
As we described previously [35], Ras transformation
caused increased AKT activation in NIH 3T3 but not RIE-
1 cells (Figure 6). However, phospho-AKT levels were
increased in ErbB2/Neu-transformed RIE-1 cells. Phos-
pho-AKT levels were efficiently reduced by the PI3K inhib-
itor LY294002 in all transformed RIE-1 cells and some
NIH 3T3 cells. Interestingly, both romidepsin and U0126
slightly increased the levels of phospho-AKT compared to
DMSO-treated NIH 3T3 and RIE-1 cells. Taken together,
our data suggest that romidepsin is not directly inhibiting
Ras transformation through the Raf-MEK-ERK or PI3K-
AKT pathway, and may instead disrupt transformation by
other means.
Discussion
Previous studies found that romidepsin displayed anti-
Ras activities when evaluated in H-Ras-transformed
mouse fibroblast model cell systems. However, whether
this inhibition is mediated by inhibition of specific Ras
effector signaling activities and whether this activity is
associated with cell cycle inhibition or enhanced apopto-
sis is unclear. Furthermore, whether romidepsin can block
transformation mediated by the Ras isoforms most com-
monly mutated in human cancers has not been addressed.
To perform a rigorous evaluation of the anti-Ras activities
of romidepsin, we studied the effects of romidepsin treat-
ment on two well-established and characterized model
cell systems that have been used extensively to study Ras
signaling and the cellular consequences of signal trans-
duction inhibitors. With growing evidence for Ras iso-
form differences in oncogenesis and well-established cell
context differences in Ras-mediated oncogeneis, an
important focus of our studies was the evaluation of K-
Ras- and N-Ras-transformed NIH 3T3 fibroblasts and RIE-
1 epithelial cells. Our results showed that romidepsin: 1)
blocks transformation induced by H-Ras as well as K-Ras
and N-Ras, 2) also blocks growth transformation induced
by B-Raf and ErbB2/Neu, 3) does not block canonical Ras
effector signaling pathways, and 4) impedes growth trans-
formation by promoting cell cycle arrest and not apopto-
sis.
We utilized two well-characterized model cell systems of
oncogenic Ras signaling and transformation. NIH 3T3
cells have been used extensively as a model system to
study Ras transformation [36,37]. Furthermore, some of
the early studies on the effects of romidepsin on Ras trans-
formation were performed in this cell line [16]. Ras trans-
formation has also been studied in the RIE-1 epithelial
cell line [37-39], and a similar intestinal epithelial cell line
(IEC) was used recently to study the effects of other HDAC
inhibitors on Ras transformation [40]. The Ras effector
pathway critical for growth transformation of these cell
lines has also been established, and a key role for the Raf
effector pathway has been established in both cell types
[20]. In light of cell context differences in Ras function
[41], our studies provide a comparison of romidepsin
activity in the fibroblastic cell type most widely used in
previous studies with activities seen in an epithelial cell
line, the cell type from which the majority of RAS muta-
tion-positive cancers arise. The advantages of using such
model cell systems include the fact that mutationally-acti-
vated Ras alone is sufficient to cause full one-step growth
transformation. Thus, while such systems lack the genetic
complexity of authentic tumor cells, these model systems
have the great advantage in possessing a clear role for
mutated Ras signaling in the continued maintenance of
growth transformation.
We showed that romidepsin inhibited both the anchor-
age-dependent and anchorage-independent growth of
NIH 3T3 and RIE-1 cells transformed by all three Ras iso-
forms, as well as by B-Raf and ErbB2/Neu. Since B-Raf is a
downstream effector of Ras, B-Raf-induced transforma-
tion is not expected to depend on Ras. Therefore, these
results suggest that romidepsin is not a specific Ras inhib-
itor. In NIH 3T3 mouse fibroblasts, we observed that
romidepsin more potently inhibited the anchorage-Journal of Molecular Signaling 2009, 4:5 http://www.jmolecularsignaling.com/content/4/1/5
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Romidepsin does not inhibit Ras-mediated ERK or AKT activation in NIH 3T3 and RIE-1 cells Figure 6
Romidepsin does not inhibit Ras-mediated ERK or AKT activation in NIH 3T3 and RIE-1 cells. NIH 3T3 (A) or 
RIE-1 (B) cells stably expressing the indicated proteins were treated with DMSO (Vehicle), 5 nM romidepsin, 10 μM U0126, or 
10 μM LY294002 for 24 h. Cell lysates were analyzed by western blotting with antibodies to total ERK1/2, phospho-ERK1/2, 
total AKT, phospho-Akt, B-Raf, pan-Ras, and vinculin (loading control). Data shown are representative at least two independ-
ent experiments.
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dependent proliferation of transformed cells when com-
pared to nontransformed cells. In contrast, in the RIE-1
epithelial cell line, we observed the same degree of
anchorage-dependent growth inhibition in nontrans-
formed, B-Raf-transformed, and Ras-transformed cells.
These results are not entirely surprising, given that differ-
ences in Ras-induced transformation between NIH 3T3
and RIE-1 cells have been well documented [25,33]. The
striking differences we observed in NIH 3T3 fibroblasts
versus RIE-1 epithelial cells highlight the value of using
two model cell systems to study inhibition of transforma-
tion and suggest that caution should be used when extrap-
olating information gleaned from a single cell line to
other systems. Our results also suggest that while
romidepsin does block Ras-mediated growth transforma-
tion, it also blocks transformation induced by other onco-
genes, and thus we do not expect that patient response to
romidepsin will be limited to tumors harboring RAS
mutations.
Recently, Klampfer et al. reported that two other HDAC
inhibitors, butyrate and suberoylanilide hydroxamic acid
(SAHA), selectively induced apoptosis under anchorage-
dependent conditions in IEC-6 rat intestinal epithelial
cells transformed with K-Ras, compared to nontrans-
formed cells [40]. These data contrast with our results in
RIE-1 cells where we found that nontransformed cells
were as sensitive to romidepsin as Ras-transformed cells.
This discrepancy may be due to differences in the proper-
ties of inhibitors used (SAHA and romidepsin are not
equivalent, and have entirely different chemical struc-
tures), the cell lines studied, and the assays used to moni-
tor apoptosis (Klampfer et al. used flow cytometry to
measure apoptosis, whereas we used caspase-3 and PARP
cleavage to detect apoptosis). Other groups have also
reported that romidepsin selectively induces caspase-3
cleavage, PARP cleavage, and apoptosis in Ras-trans-
formed cells [10,17,24,28]. However, we failed to observe
cleavage of either caspase-3 or PARP in response to
romidepsin in either vector control or Ras-transformed
cells under the conditions in which romidepsin blocked
cell proliferation. In previous studies, 10T1/2 and J82 cell
lines were used, whereas we studied NIH 3T3 and RIE-1
cell lines, so the differences in cell lines may account for
the differences in results. Indeed, in our studies here we
have shown that romidepsin treatment can have strikingly
different effects in NIH 3T3 cells compared to RIE-1 cells.
It remains possible that higher concentrations of
romidepsin or different tissue culture conditions (such as
serum-starvation) may induce apoptosis in these cells, but
we conclude that apoptosis did not significantly contrib-
ute to the decrease in anchorage-dependent or -independ-
ent growth that we observed with romidepsin. Instead, we
observed that romidepsin increased levels of the CDK
inhibitor p21 and decreased expression of cyclin D1, sug-
gesting that romidepsin blocks cell proliferation by inhib-
iting cell cycle progression rather than by induction of
apoptosis. Furthermore, we found that romidepsin treat-
ment decreased phosphorylation of Rb, which correlates
with arrest in the G1 phase of the cell cycle. These observa-
tions are consistent with observations from clinical trial
analyses, where HDAC inhibitors may cause growth arrest
in some settings and apoptosis in others. In summary, our
results suggest that RAS mutation status alone will not be
a reliable genetic marker to predict tumor cell response to
HDAC inhibition.
Previous studies have shown that romidepsin reverts the
morphology of H-Ras-transformed NIH 3T3 mouse
fibroblasts [16]. While we did observe some morphologi-
cal changes, we did not observe substantial morphologi-
cal reversion to the nontransformed phenotype in Ras-
transformed NIH 3T3 cells treated with romidepsin. In
contrast, treatment with the U0126 MEK inhibitor did
result in substantial morphological reversion, providing
further evidence against an involvement of ERK inhibition
to romidepsin activity. Differences in experimental condi-
tions and in strain differences in the NIH 3T3 cells utilized
[42] may account for these discrepancies with our NIH
3T3 results. For example, Ueda et al. transformed cells
using transfection of genomic DNA from human bladder
carcinoma EJ cells (which contain a mutated HRAS allele)
[16], whereas we retrovirally infected cells with H-, K-, or
N-Ras cDNA to obtain Ras-transformed cells. These differ-
ences in Ras transformation may contribute to the differ-
ences in results. In contrast, we did observe partial
morphological reversion in transformed RIE-1 cells, par-
ticularly those transformed with ErbB2/Neu and with N-
Ras. The greater sensitivity of N-Ras-transformed RIE-1
intestinal epithelial cells to reversion may reflect Ras iso-
form functional differences, for example, as described for
K-Ras and N-Ras in oncogenesis in a mouse model for
colon cancer development [19].
While several previous studies have investigated the
effects of romidepsin on Ras activation of the Raf and
PI3K effector pathways, as measured by phosphorylation
of ERK and AKT, no consensus has been reached. In some
studies, romidepsin has been reported to decrease levels
of phospho-ERK in H-Ras-transformed cells and in cancer
cell lines [17,21,23], whereas in others, no alterations in
the levels of phospho-ERK in Ras-transformed cells were
seen [24]. In nontransformed cells, romidepsin was
shown to increase phospho-ERK [17,24]. We did not
observe significant changes in phospho-ERK in both the
RIE-1 and NIH 3T3 transformed and nontransformed
cells. Though some reported differences may be due to dif-
ferences in romidepsin dosing regimens, we tested three
growth-inhibitory concentrations of romidepsin (2, 5,
and 10 nM) at three different time periods (6, 24, and 48Journal of Molecular Signaling 2009, 4:5 http://www.jmolecularsignaling.com/content/4/1/5
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h), and did not observe any differences in phospho-ERK
(data not shown). We also observed that romidepsin
slightly increased levels of phospho-AKT in most cell lines
tested, in agreement with Song et al [24]. This contrasts
with data from Fecteau et al., who reported that romidep-
sin increased phospho-Akt in nontransformed cells, but
decreased phospho-AKT in Ras-transformed C3H10T1/2
cells [17]. Again, the discrepancies may be due to differ-
ences in cell type or cell strain, concentration of drug, or
length of treatment. For example, Fecteau et al. used 10T1/
2 cells, which in our own analyses do exhibit different
properties than NIH 3T3 cells. Yu et al. and Kobayashi et
al. both used much higher concentrations of romidepsin
to elicit a decrease in ERK phosphorylation (25 ng/mL,
which is equivalent to 46 nM, and 100 nM, respectively)
[21,23]. Indeed, Kobayashi et al. did not observe a
decrease in ERK phosphorylation using just 10 nM of
romidepsin, consistent with our studies where 5 nM did
not reduce ERK activity, yet did reduce growth. Regardless,
our results demonstrate that in our cell models, romidep-
sin is not inhibiting growth and transformation by
directly inhibiting these two key Ras effector signaling
pathways. Thus, we suggest that ERK and AKT phosphor-
ylation will not be useful biomarkers for romidepsin
activity. Since at least three additional Ras effector path-
ways have been implicated in oncogenesis (e.g., the Ral-
GEF-Ral pathway), we cannot exclude the possibility that
romidepsin may block other Ras effector pathways. How-
ever, these effectors do not potently transform NIH 3T3 or
RIE-1 cells, making it unlikely that romidepsin inhibition
of Ras involves antagonism of Ras effector activation.
We did not find evidence for romidepsin inhibition of Ras
signaling associated with inhibition of Ras transforma-
tion. Thus, the mechanism for romidepsin inhibition of
Ras-induced transformation in our models remains
unclear. Neoplastic transformation depends on activation
of oncogenes as well as on silencing of tumor suppressor
genes [43]. Ras-induced transformation requires epige-
netic events that direct silencing of tumor suppressor and
pro-apoptotic genes [44]. Recently, Ras has been shown to
silence gene expression using a pathway consisting of
many chromatin modifiers, including HDAC9 [44].
HDAC inhibitors such as romidepsin are known to reverse
the epigenetic changes that have occurred in tumor cells,
restoring them to a more normal state. Although
romidepsin displays poor activity against the HDAC9 iso-
form, other HDAC isoforms may be required for Ras-
induced transformation. For example, HDAC6 was
recently found to be required for Ras-induced transforma-
tion [45]. HDAC inhibitors are also known to increase
expression of several cell cycle inhibitors, including
p21CIP1/WAF1 [6]. These changes in gene expression may
account for the potent growth inhibition of Ras- and Raf-
transformed cells that we observed with romidepsin.
Future gene array analyses to assess the gene expression
changes seen in romidepsin-treated nontransformed and
Ras-transformed NIH 3T3 and RIE-1 cells will be impor-
tant to further evaluate this issue.
Conclusion
In summary, while our studies showed romidepsin activi-
ties that differed from observations made by other studies,
our main conclusion, that Ras-transformed cells are sensi-
tive to romidepsin treatment, is in agreement with previ-
ous studies. Our distinct observations made with Ras-
transformed NIH 3T3 and RIE-1 cells demonstrate the
striking cell context dependence of romidepsin action.
This may also account for the highly varied observations
made in the literature concerning the multiple mecha-
nisms of anti-Ras activities described for romidepsin and
highlights the importance of using more than one model
system. We also observed that romidepsin blocked trans-
formation induced by B-Raf, suggesting that the anti-
tumor activity of romidepsin is not specific for transfor-
mation driven by Ras. Therefore, we suggest that RAS
mutation status alone will not be a reliable molecular
determinant to predict sensitivity to romidepsin. Further
analysis of romidepsin anti-tumor activity in human
tumor cell lines with and without RAS mutations will be
required to confirm this prediction.
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